首页> 外文期刊>BMC Medicine >Development and validation of the VitaL CLASS score to predict mortality in stage IV solid cancer patients with septic shock in the emergency department: a multi-center, prospective cohort study
【24h】

Development and validation of the VitaL CLASS score to predict mortality in stage IV solid cancer patients with septic shock in the emergency department: a multi-center, prospective cohort study

机译:重要阶级评分的发展与验证,以预测急诊部静脉休克阶段静脉癌症患者死亡率:多中心,前瞻性队列研究

获取原文
           

摘要

Clinical decision-making of invasive high-intensity care for critically ill stage IV cancer patients in the emergency department (ED) is challenging. A reliable and clinically available prognostic score for advanced cancer patients with septic shock presented at ED is essential to improve the quality of intensive care unit care. This study aimed to develop a new prognostic score for advanced solid cancer patients with septic shock available early in the ED and to compare the performance to the previous severity scores. This multi-center, prospective cohort study included consecutive adult septic shock patients with stage IV solid cancer. A new scoring system for 28-day mortality was developed and validated using the data of development (January 2016 to December 2017; n?=?469) and validation sets (January 2018 to June 2019; n?=?428). The developed score’s performance was compared to that of the previous severity scores. New scoring system for 28-day mortality was based on six variables (score range, 0–8): vital signs at ED presentation (respiratory rate, body temperature, and altered mentation), lung cancer type, and two laboratory values (lactate and albumin) in septic shock (VitaL CLASS). The C-statistic of the VitaL CLASS score was 0.808 in the development set and 0.736 in the validation set, that is superior to that of the Sequential Organ Failure Assessment score (0.656, p?=?0.01) and similar to that of the Acute Physiology and Chronic Health Evaluation II score (0.682, p?=?0.08). This score could identify 41% of patients with a low-risk group (observed 28-day mortality, 10.3%) and 7% of patients with a high-risk group (observed 28-day mortality, 73.3%). The VitaL CLASS score could be used for both risk stratification and as part of a shared clinical decision-making strategy for stage IV solid cancer patients with septic shock admitting at ED within several hours.
机译:急诊阶段IV阶段急性癌症患者的临床决策急诊部(ED)是挑战性的。在ED呈现出脓毒症震惊的高级癌症患者的可靠和临床可行的预后分数对于提高重症监护单元护理的质量至关重要。本研究旨在为先进的抗化性休克患者发育新的预后分数,并在ed早期可用,并将性能与先前的严重性分数进行比较。这个多中心,前瞻性队列研究包括连续的成人脓疼痛患者,患有阶段IV阶段的癌症。使用发展数据(2016年1月至2017年12月)制定和验证了28天死亡率的新评分系统; N?=?469)和验证集(2018年1月至2019年6月; N?=?428)。将发达的分数的性能与先前的严重性分数进行了比较。 28天死亡率的新评分系统基于六个变量(得分范围,0-8):ED演示文稿(呼吸率,体温和改变的调节),肺癌类型和两个实验室值(乳酸和白蛋白)在化粪池休克(重要阶级)。在开发集中的生命类别得分的C统计数据为0.808,验证集中的0.736,这优于顺序器官失效评估评分(0.656,P?= 0.01),类似于急性的生理学和慢性健康评估II分数(0.682,p?= 0.08)。该分数可以鉴定41%的患者低风险群体(观察到28天死亡率,10.3%)和7%的高风险群体(观察到28天死亡率,73.3%)。重要的阶级得分可用于风险分层,作为阶段IV阶段患者的共同临床决策策略的一部分,在几小时内在ED中在ED中致密。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号